Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
STK Bio-ag Technologies is an Israel-based biotechnology company specializing in the development and commercialization of botanical-based biopesticides for sustainable agriculture. The company is best known for its flagship product, Timorex Gold, a bio-fungicide derived from tea tree oil that is used globally to protect crops from various fungal and bacterial diseases. STK pioneered "Hybrid" technology, which integrates biological and synthetic chemical active ingredients into a single formulation to enhance efficacy and manage resistance. Their product portfolio, including the hybrid fungicide REGEV, aims to reduce chemical residues in food while maintaining high crop yields for growers. STK operates in over 30 countries and serves a wide range of agricultural sectors, including fruits, vegetables, and broad-acre crops.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on STK Bio-ag Technologies.